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Abstract
Introduction:  In  obstructive  hypertrophic  cardiomyopathy  (HCM),  alcohol  septal  ablation  (ASA)
can lead  to  gradient  reduction  and  symptom  improvement.  We  aimed  to  assess  the  efficacy  and
safety  of  ASA  in  a  long-term  outcome  study.
Methods:  We  analyzed  patients  who  underwent  ASA  over  a  seven-year  period  in  a  tertiary  cen-
ter.  The  primary  echocardiographic  endpoint  was  >50%  reduction  in  left  ventricular  outflow  tract
(LVOT)  gradient  within  a  year  of  the  procedure.  The  primary  clinical  endpoints  were  improve-
ment  in  functional  capacity  and  a  combined  endpoint  of  cardiac  death  and  rehospitalization
for cardiac  cause.  The  follow-up  period  was  4.17±2.13  years.
Results:  A  total  of  80  patients,  mean  age  63.9±12.3  years,  30.0%  male,  were  analyzed.  Baseline
LVOT gradient  was  96.3±34.6  mmHg  and  interventricular  septal  thickness  was  21.6±3.1  mm.
Minor  complications  were  observed  in  6.3%  and  major  complications  in  2.5%,  and  8.8%  received
a  permanent  pacemaker.
The primary  echocardiographic  endpoint  was  achieved  by  85.7%.  At  three-month  follow-
up,  LVOT  gradient  was  25.8±26.0  mmHg  in  the  successful  procedure  group,  compared  to
69.2±35.6  mmHg  in  the  other  patients  (p=0.001).  At  six  months,  LVOT  gradient  was  27.1±27.4
vs.  58.2±16.6  mmHg  (p=0.024).  Among  74  patients  in  NYHA  class  III/IV  before  the  procedure,  57
(77%)  improved  to  NHYA  class  I/II.  The  combined  primary  clinical  endpoint  (cardiac  death  and
rehospitalization  for  cardiac  cause)  was  observed  in  27.5%  (n=22).  In  the  unsuccessful  group,
the  combined  endpoint  was  observed  in  54.5%,  compared  to  only  22.7%  in  the  successful  group.
Only  two  patients  died  of  cardiac  causes.
Conclusion:  ASA  is  a  safe  procedure  with  a  high  success  rate.  Patients  who  achieved  significant
reductions in  LVOT  gradient  suffered  less  cardiac  death  and  rehospitalization  for  cardiac  cause.
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Gradiente  na  câmara
de saída  do
ventrículo  esquerdo
Desfecho  a  curto  e  longo  prazo  após  ablação  septal  alcoólica  na  miocardiopatia
hipertrófica  obstrutiva  --  experiência  num  centro  de  referência
Resumo
Introdução: Na miocardiopatia  hipertrófica  obstrutiva  (MCHO),  ablação  septal  alcoólica  (ASA)
pode levar  a  redução  do  gradiente  e  melhoria  sintomática.  O  objetivo  foi  avaliar  a  eficácia  e
segurança da  ASA  no  desfecho  a  longo  prazo.
Métodos:  Análise  de  doentes  submetidos  a  ASA,  durante  sete  anos,  num  centro  terciário.
Endpoint primário  ecocardiográfico:  redução  >50%  do  gradiente  na  câmara  de  saída  do  ven-
trículo  esquerdo  (CSVE)  durante  o  primeiro  ano  após  o  procedimento.  Endpoints  primários
clínicos:  a)  melhoria  da  capacidade  funcional;  b)  endpoint  combinado:  morte  de  causa
cardíaca+hospitalização  de  causa  cardíaca.  Tempo  de  seguimento  4,17±2,13  anos.
Resultados: Oitenta  doentes,  idade  média  de  63,9±12,3  anos,  30,0%  homens.  De  base,  o
gradiente na  CSVE  era  96,3±34,6  mmHg,  espessura  do  septo  interventricular  21,6±3,1  mm.
Complicações  minor  foram  verificadas  em  6,3%,  complicações  major  em  2,5%  e  8,8%  receberam
um  pacemaker  definitivo.  O  endpoint  primário  ecocardiográfico  foi  atingido  em  85,7%.  Aos  três
meses,  o  gradiente  na  CSVE  foi  de  25,8±26,0  mmHg  no  grupo  com  sucesso  no  procedimento  con-
trastando  com  69,2±35,6  mmHg  nos  restantes  doentes  (p=0,001).  Aos  seis  meses,  os  gradientes
na  CSVE  foram  27,1±27,4  versus  58,2±16,6  mmHg  (p=0,024).
De  entre  os  74  doentes  em  classe  NYHA  III/IV  antes  do  procedimento,  57  (77%)  melhoraram
para classe  NYHA  I/II.  O  endpoint  primário  combinado  (morte  de  causa  cardíaca+hospitalização
de causa  cardíaca)  verificou-se  em  27,5%  (n=22).  No  grupo  sem  sucesso,  o  endpoint  primário
composto  verificou-se  em  54,5%,  contrastando  com  apenas  22,7%  no  grupo  com  sucesso.  Apenas
dois  doentes  apresentaram  morte  de  causa  cardíaca.
Conclusão:  A  ASA  é  um  procedimento  seguro  com  elevada  taxa  de  sucesso.  Doentes  que  atin-
giram redução  significativa  do  gradiente  na  CSVE  apresentam  menor  morte  de  causa  cardíaca
e  hospitalização  de  causa  cardíaca.
© 2019  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é  um










































ypertrophic  cardiomyopathy  (HCM)  is  defined  by  the
resence of  unexplained  asymmetric  left  ventricular  (LV)
ypertrophy associated  with  non-dilated  ventricular  cham-
ers that  cannot  be  explained  by  cardiac  or  systemic
isease, including  abnormal  loading  conditions.1,2 Its
revalence in  the  general  population  is  estimated  at  approx-
mately 1:500.3 However,  recent  information  on  its  genetic
asis in  pathogenic  mutations  has  led  to  the  prevalence  of
CM gene  carriers  being  estimated  at  1:200.4 In  about  60%
f cases,  transmission  of  the  disease  is  autosomal  dominant,
aused by  mutations  in  cardiac  sarcomere  protein  genes.5
Dynamic  left  ventricular  outflow  tract  (LVOT)  obstruc-
ion is  a  hallmark  of  the  disease,  caused  by  systolic  anterior
otion (SAM)  of  the  anterior  mitral  leaflet.6 The  presence
f LVOT  obstruction,  defined  as  a  resting  systolic  gradient
f >30  mmHg  in  the  LVOT,  has  been  associated  with  worse
utcome, and  can  lead  to  heart  failure,  arrhythmic  events,
troke and  death.2,7--9 Studies  have  shown  that  reduction  of
VOT obstruction  by  surgery  or  percutaneous  alcohol  septal
blation (ASA)  improves  prognosis.10--12According  to  the  current  guidelines,  symptomatic
atients in  New  York  Heart  Association  (NYHA)  class  ≥III
nd/or with  recurrent  exertional  syncope,  refractory  to





radient  ≥50  mmHg,  are  candidates  for  septal  reduction
ntervention (class  I  recommendation,  level  of  evidence
).2 The  decision  between  a  surgical  or  a  percutaneous
pproach depends  on  mitral  valve  and  septal  anatomy  and
he presence  of  other  lesions  requiring  surgical  intervention.
The  aim  of  the  present  study  was  to  assess  the  efficacy
nd safety  of  ASA  and  its  long-term  outcome.
ethods
tudy  design
e  analyzed  consecutive  patients  who  underwent  ASA  in
 reference  center.  The  data  were  collected  prospectively
etween beginning  the  procedure  in  January  2009  and  June
017.
Selected patients  presented  NYHA  class  III  or  IV,  Cana-
ian Cardiovascular  Society  (CCS)  class  II or  III  angina,
r exertional  syncope  for  which  an  arrhythmic  cause
ad been  excluded.  Dynamic  obstruction  was  defined  as
50 mmHg  at  rest  and/or  ≥70  mmHg  with  provocation.
inimum basal  septal  thickness  was  >16  mm,  given  the  risk
f causing  an  iatrogenic  interventricular  communication.
ignificant functional  mitral  regurgitation  due  to  SAM  was
ot considered  a  contraindication  for  ASA,  but  in  cases
rophic  cardiomyopathy  475
Table  1  Baseline  clinical  characteristics  of  the  overall
population.
Age,  years  63.9±12.3
Male,  n  (%)  24  (30.0)
NYHA  class  III/IV,  n  (%)  74  (92.5)
CCS  class  II/III,  n  (%)  42  (52.5)
Syncope,  n  (%)  6  (7.5)
Hypertension,  n  (%) 47  (58.8)
Diabetes,  n  (%) 6  (7.5)
Dyslipidemia,  n  (%) 34  (42.5)
Coronary  disease,  n  (%)  7  (8.8)
Atrial  fibrillation,  n  (%)  14  (17.5)
Previous  PPM,  n  (%)  10  (12.5)
Maximum  septal  thickness,  mm  21.6±3.1
LVOT  gradient,  mmHg  96.3±34.6
Moderate  MR,  n  (%)  26  (32.5)
SAM,  n  (%)  36  (45.0)
LV  diameter,  mm  45.6±8.1
LA  diameter,  mm  47.8±8.9
PASP,  mmHg  46.3±18.1
Beta-blocker,  n  (%)  63  (78.8)
CCB,  n  (%) 34  (42.5)
CCB: calcium channel blocker; CCS: Canadian Cardiovascular
Society; LA: left atrial; LV: left ventricular; LVOT: left ventricular
outflow tract; MR: mitral regurgitation; NYHA: New York Heart
Association; PASP: pulmonary artery systolic pressure; PPM: per-




















Outcome  after  alcohol  septal  ablation  in  obstructive  hypert
of  concurrent  regurgitation  mechanism  myectomy  should
be performed.  In  the  presence  of  severe  hypertrophy
(>30 mm),  mid-ventricular  gradient  and  LVOT  obstruction
caused by  the  papillary  muscle,  surgical  myectomy  was
the procedure  of  choice.  The  patients  who  underwent  ASA
in our  sample  were  considered  at  high  risk  for  surgery  or
expressed their  personal  preference  for  ASA.
Baseline  clinical  characteristics  including  demographic
characteristics, heart  failure  symptoms,  presence  of  angina
and comorbidities  were  collected  for  all  patients.
Major  complications  were  defined  as  those  resulting  in
death or  significant  morbidity  or  life-threatening  events  dur-
ing the  procedure  or  follow-up.13 Heart  failure  was  classified
according to  NYHA  functional  class.
All  patients  were  followed  periodically.  In  addition  to  out-
patient clinical  visits,  telephone  follow-up  was  performed  to
check for  the  presence  of  symptoms  and  the  occurrence  of
cardiac events.
In the  majority  of  patients  a  dedicated  echocardiogram
was performed  at  three  months  and/or  within  12  months  of
the procedure.  End-diastolic  interventricular  septal  thick-
ness was  assessed  by  M-mode  and  2D  echocardiography  in
parasternal long-axis  view  and  4  chambers.  LVOT  gradient
at rest  and  after  provocation  with  Valsalva  maneuver  was
assessed by  a  combination  of  color  Doppler,  pulsed  wave
Doppler and  continuous  wave  Doppler  echocardiography.
Mitral regurgitation  was  assessed  by  color  Doppler  and  in
some cases  by  the  proximal  isovelocity  surface  area  method.
The  procedure  was  defined  as  successful  when  a  >50%




The primary  echocardiographic  endpoint  was  >50%  reduction
in LVOT  gradient  within  a  year  of  the  procedure.
The  primary  clinical  endpoints  were  improvement  in
functional capacity  and  a  combined  endpoint  of  cardiac
death and  rehospitalization  for  cardiac  cause.
The  primary  safety  endpoint  was  a  combination  of  in-
hospital mortality  and  major  complications.
Secondary endpoints
The secondary  echocardiographic  endpoint  was  improve-
ment in  mitral  regurgitation,  and  the  secondary  clinical
endpoint was  a  combination  of  all-cause  mortality  and
rehospitalization.
Alcohol septal  ablation
ASA was  performed  in  a  standard  fashion  as  previously
described.13,14 The  septal  branch  of  the  left  coronary  artery
was chosen  by  invasive  angiography.  An  angioplasty  balloon
was inflated  in  the  proximal  portion  of  the  septal  branch
and 1-2  ml  of  SonoVue
®
echocardiographic  contrast  (Bracco,
Milan, Italy)  was  injected  through  the  balloon  lumen.  The
selected artery  was  assessed  by  contrast  echocardiography
as a  suitable  target  for  ASA.  If  the  branch  constituted  a  good
choice, 0.1  ml  alcohol  per  cm  thickness  was  infused  at  a  rate





The  risk  of  need  for  permanent  pacemaker  was  estimated
sing the  criteria  described  by  Faber  et  al.15
tatistical  analysis
he  statistical  analysis  was  performed  using  IBM  SPSS  Statis-
ics (IBM  SPSS,  Chicago,  IL).  Continuous  variables  were
xpressed as  mean  ±  standard  deviation  and  categorical
ariables were  expressed  as  absolute  number  and  percent-
ge. Normality  was  assessed  using  the  Shapiro-Wilk  test.
tudy groups  (successful  vs.  unsuccessful)  were  compared
sing the  Student’s  t  test  or  the  Wilcoxon-Mann-Whitney
est for  continuous  variables,  and  Pearson’s  chi-square  or
isher’s exact  test  for  categorical  measures,  as  appropriate.
 p-value  <0.05  was  considered  statistically  significant.
esults
uring  the  study  period,  ASA  was  performed  in  80  patients,
ean age  63.9±12.3  years,  30.0%  male.  The  baseline  clini-
al characteristics  of  the  study  population  are  presented  in
able 1.
Regarding clinical  features,  most  patients  (92.5%)  pre-
ented NYHA  class  III  or  IV  heart  failure,  around  half  (52.5%)
resented CCS  class  II  or  III  angina,  and  only  7.5%  presented
yncope.
As shown  in  Table  1,  mean  LVOT  gradient  at  baseline
as 96.3±34.6  mmHg  and  maximum  septal  thickness  was
1.6±3.1 mm.  Regarding  the  mitral  valve,  45.0%  of  patients
































































resented  SAM  and  32.5%  presented  moderate  mitral  regur-
itation (≥II/IV).
Reflecting  septal  thickness,  the  mean  alcohol  dose  was
.04±0.36 ml.  Mean  peak  creatine  kinase  was  1233.6±
91.2 U/l.
Six minor  complications  were  observed  in  6.3%  of  patients
n=5), including  infection  in  two  patients  resolved  by
ntibiotic therapy,  rapid  atrial  fibrillation  in  one  patient
ontrolled with  pharmacological  therapy,  acute  pulmonary
dema in  one  patient  resolved  with  medical  management
nly, and  vascular  access  site  complications  in  two  patients
ithout need  for  surgical  intervention.
Major  complications  were  observed  in  2.5%  of  patients
n=2), consisting  of  one  case  of  electrocatheter-related  car-
iac tamponade  resolved  by  pericardiocentesis,  and  one
ase of  inferior  infarction  caused  by  recruitment  of  the  col-
aterals  of  the  target  vessel  to  the  posterior  interventricular
ranch.
Atrioventricular block  was  observed  in  45.0%  of  patients
n=36), in  the  majority  of  cases  transiently  during  ASA
nd/or within  12  hours  of  the  procedure.  Only  8.8%  of
atients received  a  permanent  pacemaker  for  atrioven-
ricular block,  of  whom  two  received  an  implantable
ardioverter-defibrillator  (ICD)  due  to  non-sustained  ven-
ricular tachycardia  previously  documented  on  Holter
onitoring, and  another  patient  due  to  risk  of  cardiac
udden death  of  6%  estimated  by  a  validated  scoring
ystem.2
Redo  ASA  was  performed  in  eight  patients  (10.0%)  and
urgical myectomy  in  two  patients  (2.5%)  due  to  recurrence
f LVOT  gradient  and  symptoms  and  lack  of  a  target  septal
ranch, respectively.
Significant reductions  in  mean  septal  thickness  were
een, from  21.6±3.1  mm  at  baseline  to  15.0±1.6  mm
n echocardiographic  assessment  three  months  after  ASA
p=0.003) (Figure  1).Subsequent  echocardiographic  parameters  after  ASA
ere missing  in  three  patients  who  were  followed  at  differ-





















igure  2  Comparison  of  left  ventricular  outflow  tract  (LVOT)  gradi
p.ssessed by  echocardiography  at  three  months  after  alcohol
eptal ablation  (ASA).
chieved  by  66  patients  (85.7%).  At  three-month  follow-
p, LVOT  gradient  in  the  overall  population  was  30.2±
1.3 mmHg.  As  shown  in  Figure  2,  mean  LVOT  gradient  was
ignificantly lower  in  the  successful  group  (25.8±26.0  mmHg
ompared to  69.2±35.6  mmHg  in  the  unsuccessful  group;
=0.001). At  six  months,  mean  LVOT  gradient  was  33.1±
8.3 mmHg  in  the  overall  population,  substantially  lower
n the  successful  group  (27.1±27.4  mmHg  vs.  58.2±16.6
mHg; p=0.024)  (Figure  2).  In  terms  of  baseline  charac-
eristics, there  were  no  significant  differences  between
atients who  achieved  and  who  did  not  achieve  the  primary
chocardiographic endpoint.  There  were  also  no  significant
ifferences in  alcohol  administration  or  peak  creatine
inase between  the  two  groups  (Table  2).
Regarding  the  primary  clinical  endpoints,  improvement  in
unctional capacity  was  achieved  in  the  majority  of  patients.
f the  74  patients  in  NYHA  class  III/IV  before  the  procedure,
7 (77%)  improved  to  NHYA  class  I/II.  The  combined  primary










ent  between  successful  and  unsuccessful  groups  during  follow-
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Table  2  Comparison  between  successful  and  unsuccessful  groups.
Characteristics  Successful  (n=66)  Unsuccessful  (n=11)  p
Age,  years  64.9±11.5  56.5±16.1  0.173
Male,  %  33.3  18.2  0.265
Hypertension,  %  62.3  54.5  0.684
Diabetes,  %  6.3  18.2  0.377
Dyslipidemia,  %  45.3  45.5  0.835
Dyspnea,  %  90.8  100  0.576
NYHA  class  III,  %  87.5  90.9  0.607
NYHA  class  IV,  %  7.8  0  0.442
Angina,  % 53.8  45.5  0.780
Baseline  septal  thickness,  mm 21.3±2.9 23.4±4.4 0.490
Baseline  LVOT  gradient,  mmHg 96.0±34.4 80.1±21.5 0.154
SAM,  %  50.0  18.1  0.050
Moderate  MR,  %  34.8  27.3  0.623
LV  diameter,  mm  46.3±8.7  41.7±6.8  0.206
LA  diameter,  mm  47.8±8.9  47.8±9.6  0.991
PASP,  mmHg  47.0±18.6  37.5±3.6  0.488
Beta-blocker,  %  78.5  81.8  1.000
CCB,  %  47.7  27.3  0.327
Sinus  rhythm,  %  87.5  90.0  1.000
Alcohol,  ml  2.07±0.27  2.04±0.33  0.747
Peak  creatine  kinase,  U/l  1233.1±600.3  1106.3±555.5  0.551
CCB: calcium channel blocker; LA: left atrial; LV: left ventricular; LVOT: left ventricular outflow tract; MR: mitral regurgitation; NYHA:
New York Heart Association; PASP: pulmonary artery systolic pressure; 
Success was defined as achievement of the primary echocardiographic 
Combined primary clinical endpoint












Figure  3  Comparison  of  combined  primary  endpoint  (car-




















Discussionsuccessful and  unsuccessful  groups.  Success  was  defined  as
achievement of  the  primary  echocardiographic  endpoint.
cardiac  cause  was  observed  in  27.5%  of  patients  in  the  over-
all population  (n=22)  during  a  follow-up  of  3.9±2.3  years.
In patients  who  did  not  present  LVOT  gradient  reduction  of
>50% (the  criterion  for  procedural  success),  the  combined
primary endpoint  was  observed  in  more  than  half  (54.5%),
compared to  only  22.7%  of  patients  with  procedural  success
(p=0.038) (Figure  3).  Only  two  patients  (2.7%)  died  of  car-
diac causes,  one  from  septic  shock  after  surgical  myectomy
55 months  after  ASA  and  the  other  from  cardiogenic  and




SAM: systolic anterior motion of the anterior mitral leaflet.
endpoint.
The  safety  endpoint  was  observed  in  three  patients
3.8%), including  two  major  complications  and  one  in-
ospital death,  as  described  above.
Concerning  the  secondary  endpoints,  among  the
6 patients  with  moderate  mitral  regurgitation  at  base-
ine, 50%  improved  to  mild  regurgitation,  as  assessed  by
ollow-up echocardiography.
The  secondary  clinical  endpoint  (all-cause  mortality  and
ehospitalization) was  observed  in  40.0%  of  the  patients
n=32), with  four  deaths  of  non-cardiac  cause  (two  from  can-
er, one  from  sepsis  and  one  from  pulmonary  embolism).  Two
f the  non-cardiac  deaths  occurred  within  a  year  of  ASA  (11
nd 12  months  after  the  procedure).
During  follow-up  one  patient  received  an  ICD  due  to  ven-
ricular fibrillation  induced  in  electrophysiological  study.
In  the  four  patients  with  ICDs  (one  implanted  before
SA), no  sustained  ventricular  arrhythmic  events  were  doc-
mented by  the  device  and  only  one  patient  presented
on-sustained ventricular  tachycardia.  In  the  other  patients,
on-sustained ventricular  tachycardia  was  documented  on
olter monitoring  in  13  patients  (16.3%)  and  ventricular
riplets in  five  (6.3%).  No  sustained  ventricular  tachycardia
as documented  on  Holter  recordings.
Results  on  the  efficacy  and  safety  of  the  procedure  are
ummarized in  Table  3.he  present  article  demonstrates  the  efficacy  and  safety  of
SA, as  well  as  its  benefit  in  short-  and  long-term  outcomes.
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Table  3  Efficacy  and  safety  of  alcohol  septal  ablation.
Efficacy
Primary  echocardiographic  endpoint:  >50%  reduction  in  LVOT  gradient  during  1st  year  85.7%
Primary  clinical  endpoints
Improvement in  functional  capacitya 77.0%
Combined  endpoint:  cardiac  death  and  rehospitalization  for  cardiac  causeb 27.5%
Secondary  echocardiographic  endpoint:  improvement  in  mitral  regurgitationc 50%
Secondary  clinical  endpoint:  all-cause  mortality  and  rehospitalizationb 40.0%
Safety
Primary  safety  endpoint:  in-hospital  mortality  and  major  complication  3.8%
Major  complications  2.5%
Minor  complications  6.3%
Atrioventricular  block  (transient  or  permanent)  45.0%
Permanent  pacemaker  implantation  8.8%
Redo  ASA/surgical  myectomy  12.5%
ASA: alcohol septal ablation; LVOT: left ventricular outflow tract; NYHA: New York Heart Association.



































































Follow-up of 3.9±2.3 years.
c Improvement from moderate to mild mitral regurgitation.
Successful  ASA,  defined  by  a  primary  echocardiographic
ndpoint of  a  >50%  LVOT  gradient  reduction  within  a year
f the  procedure,  was  achieved  in  85.7%  of  our  population,
ith residual  LVOT  gradients  of  20-30  mmHg,  consistent  with
ublished studies.16--19
ASA  reduces  gradients  by  increasing  LVOT  area,  resul-
ing in  symptomatic  relief,  improvement  of  systolic  and
iastolic function,  reduction  of  mitral  regurgitation  and
mprovement of  coronary  flow  reserve.18,20--24 The  reduc-
ion in  LVOT  gradient  leads  to  a  decrease  in  afterload
nd consequent  increase  in  cardiac  output.  As  a  result
f these  hemodynamic  changes,  diastolic  pressure  in  the
orta increases  and  diastolic  pressure  in  the  LV  chamber
ecreases, resulting  in  higher  coronary  filling  pressure  and
etter myocardial  perfusion,  improving  LV  performance.
egarding diastolic  function,  previous  studies  based  on
ssessment by  pressure-volume  loops  or  echocardiography
howed improvement  in  myocardial  relaxation  properties,
articularly active  relaxation,  leading  to  better  diastolic
ompliance and  distensibility.18,25,26
It  should  be  borne  in  mind  that  the  maximum  benefi-
ial effect  of  LVOT  gradient  reduction  is  achieved  when
nal remodeling  and  scarring  occur,  usually  more  than  three
onths after  the  procedure.27 Echocardiographic  assess-
ent during  the  first  year  of  follow-up,  rather  than  only
n the  first  few  months,  is  therefore  essential  to  deter-
ine definitive  procedural  success.28 Yoeger  et  al.  described
 ‘triphasic’  gradient  response,  consisting  of  an  early
eduction immediately  after  ASA  as  a  result  of  decreased
ontractility of  stunned  myocardium  after  ischemia,  fol-
owed by  a  rebound  in  gradient  when  contractility  recovers,
nd the  final  reduction  after  three  months,  as  described
bove.27
In  line  with  previous  studies,  we  also  achieved  significant
eductions in  NHYA  functional  class  and  in  severity  of  mitral
19,24,28egurgitation in  the  majority  of  patients. Baseline
nterventricular septal  diameter  was  significantly  reduced
fter ASA,  as  demonstrated  by  follow-up  echocardiograms,





Although  we  found  no  significant  differences  in  baseline
haracteristics between  successful  and  unsuccessful  groups,
revious studies  identified  larger  quantities  of  injected  alco-
ol, higher  baseline  LV  ejection  fraction  and  LVOT  outflow
radient, post-procedural  bundle  branch  block  on  ECG,  and
lder age  as  independent  predictors  of  significant  reduction
n LVOT  gradient.19
According  to  the  current  European  guidelines  on  HCM,
SA may  be  less  effective  in  the  presence  of  very  severe
ypertrophy (≥30  mm)  and  extensive  septal  scarring.2 In
ases of  mid-cavity  obstruction  or  a  secondary  cause  of
itral regurgitation  apart  from  SAM,  surgical  myectomy
hould be  the  procedure  of  choice.
Regarding  safety,  high-degree  atrioventricular  block  is
he most  frequent  complication.  Its  incidence  has  decreased
ith the  use  of  contrast  echocardiography  to  guide  alcohol
njection and  identify  the  target  area  at  risk,  and  the  use  of
maller quantities  of  alcohol.  In  our  experience,  most  cases
ere transient,  presumably  due  to  perinecrotic  inflamma-
ion, and  only  8.8%  of  cases  needed  a  permanent  pacemaker
ue to  permanent  conduction  tissue  damage.  Our  results
re in  agreement  with  previous  series  that  observed  a  pace-
aker implantation  rate  of  less  than  10%.16,17,19
A  study  with  contrast-enhanced  cardiac  magnetic  res-
nance imaging  confirmed  that  infarct  size  correlated
ith alcohol  volume  and  electrocardiographic  changes  with
nfarct location.30
Procedure-related  complications  included  one  case  of
ardiac tamponade,  one  of  inferior  myocardial  infarction
nd two  of  vascular  access  site  complications  without
eed for  surgical  intervention.  Cardiac  tamponade  has  been
eported as  a  complication  of  ASA  in  previous  series.19,31
here  was  only  one  in-hospital  death,  16  days  after  ASA,  not
econdary  to  a  procedure-related  complication.  This  patient
as in  NYHA  class  IV  with  mid-ventricular  obstruction,  andhe procedure  was  a  palliative  intervention.  These  findings
onfirm the  low  mortality  associated  with  this  procedure
eported in  the  literature,  even  in  high-risk  patients.32,33 In














Outcome  after  alcohol  septal  ablation  in  obstructive  hypert
7.2%  and  mortality  of  cardiac  cause  of  2.5%.  In  our  series
there was  only  one  death  (1.3%)  in  the  first  30  days  after
ASA, in  line  with  a  systematic  review  by  Alam  et  al.  which
reported mean  30-day  mortality  of  1.5%  (0.0-5.0%).34
Despite  concerns  about  ventricular  arrhythmias  sec-
ondary to  a  permanent  arrhythmogenic  substrate  generated
by ASA  scarring,  published  studies  have  not  shown  increased
incidence of  arrhythmic  events  after  ASA.  In  our  study  no
sustained ventricular  arrhythmic  events  were  recorded  dur-
ing follow-up.
During a  long  follow-up  (mean  of  3.9±2.3  years  since
beginning the  procedure  in  January  2009),  cardiac  events
including hospitalization  and  death  occurred  mainly  in
patients in  whom  significant  reduction  of  LVOT  gradient  was
not achieved.  The  mean  annual  cardiac  mortality  of  0.5%  and
annual all-cause  mortality  of  1.0%  in  our  study  were  slightly
less than  in  the  series  by  Steggerda  et  al.  (0.7%  and  1.5%,
respectively).31
With  regard  to  efficacy  and  safety,  ASA  can  now  be  consid-
ered as  an  alternative  to  surgery,  presenting  the  advantage
of being  a  percutaneous  procedure  that  does  not  require
sternotomy and  is  therefore  associated  with  shorter  recov-
ery times.  The  technique  can  also  be  used  in  patients  with
contraindications for  surgery  due  to  age  or  comorbidities.
However, when  mitral  valve  repair  is  needed  and  in  cases
requiring a  larger  quantity  of  hypertrophied  muscle  to  be
resected, surgery  should  be  the  first  option.  The  long-term
outcomes are  similar  between  the  two  approaches  in  func-
tional class,  LVOT  gradient  reduction,  mitral  abnormalities
and ventricular  arrhythmias.3,34 With  ASA,  periprocedural
complications  are  less  frequent  and  hospital  stay  is  shorter.31
Nevertheless,  there  is  more  frequently  need  for  perma-
nent pacemaker  implantation  with  ASA,  and  immediately
after the  procedure  LVOT  gradients  are  higher  with  this
technique.31,34,35
Our  study  has  some  limitations.  The  study  sample  size
inevitably reflects  the  limitations  of  a  single-center  experi-
ence. However,  given  the  relatively  small  number  of  patients
who have  undergone  this  technique,  a  larger  study  popula-
tion would  prove  difficult  to  achieve,  except  in  multicenter
studies. Referral  for  ASA  was  based  on  therapeutic  deci-
sions made  by  referring  physicians,  and  it  is  likely  that  some
patients with  formal  indication  were  not  referred.  As  our
department is  a  reference  center,  some  patients  are  fol-
lowed in  other  centers,  and  consequently  in  these  patients
follow-up data  were  obtained  only  by  telephone,  which
can lead  to  errors  in  classification  of  functional  capacity
and recording  of  cardiac  events  and  complications.  Further-
more, the  study  did  not  include  a  control  group  to  compare
the outcomes  in  a  similar  population  that  did  not  undergo
ASA.
Conclusion
ASA  has  a  high  success  rate  in  patients  with  obstructive  HCM,
with significant  decreases  in  LVOT  gradient,  improvement  of
functional capacity  and/or  reduction  of  mitral  regurgitation
in most  cases.  Patients  who  achieve  significant  reductions
in LVOT  gradient  suffered  less  cardiac  death  and  cardiac
rehospitalization for  cardiac  cause.
1
ic  cardiomyopathy  479
ASA is  also  a  safe  procedure,  most  cases  of  high-degree
trioventricular block  being  transient,  with  a  rate  of  perma-
ent pacemaker  implantation  below  10%.
Considering  its  efficacy  and  safety  profile,  ASA  can  now
e considered  as  an  alternative  to  surgery  in  patients  with
bstructive HCM.
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